Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus PROMETH FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus PROMETH FORTIS.
CLARINEX-D 12 HOUR vs PROMETH FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, with additional anticholinergic, antiemetic, and sedative properties. It blocks histamine at H1 receptors, reducing allergic symptoms and motion sickness, and exerts antiemetic effects by blocking dopamine D2 receptors in the chemoreceptor trigger zone.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
Adults: 12.5-25 mg intramuscular or intravenous every 4-6 hours as needed for nausea. For severe nausea up to 50 mg IM/IV. Maximum single dose 50 mg, maximum daily dose 200 mg.
None Documented
None Documented
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Terminal elimination half-life: 9–16 hours (mean ~12 hours). In children and elderly, half-life may be prolonged (up to 20 hours).
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Primarily renal as inactive metabolites; <1% excreted unchanged. Total elimination: renal ~70%, fecal ~30%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine